Non-Steroidal Psoriasis Therapy Reports Symptom Reduction
A Drug Target Review brief reports a promising psoriasis therapy reducing symptoms without corticosteroids, but names no drug, no PASI data and no trial design.
Topic
Drug Pipeline
Topic
Drug Pipeline
First Human Data on Experimental Eczema Therapy Set for November
First-in-human data on an experimental eczema treatment arrives in November — from healthy volunteers, meaning safety, not effica…
FDA Clears EB06 Phase 2 Vitiligo Study IND Application
The FDA has cleared the IND for a Phase 2 study of EB06 in vitiligo, advancing the investigational candidate into mid-stage testi…
EADV 2026 Preview: Five Atopic Dermatitis Headlines Dermatologists Will Track
EADV 2026 is coming, and atopic dermatitis is already dominating the preview coverage. HCPLive flags five AD headlines clinicians…
Tilrekimig Clears EASI-75 Endpoint in Atopic Dermatitis
Tilrekimig has hit the EASI-75 primary endpoint in atopic dermatitis, with Eric Simpson, MD walking through the readout for HCPLi…
GX-03 Phase 2 Program Widens to Cover Full Atopic Dermatitis Spectrum
The GX-03 Phase 2 program has expanded to cover the full atopic dermatitis spectrum, widening the candidate's mid-stage developme…
TrenibotulinumtoxinE: A New Toxin Name Dermatologists Should Know
TrenibotulinumtoxinE is an early-stage type E botulinum toxin candidate, distinct from all approved type A products. Its reported…
Mendelian randomization maps causal omics in atopic dermatitis
Frontiers review applies Mendelian randomization across stacked omics layers in atopic dermatitis, reframing eczema genetics as a…
Palvella to Present Three Posters on Microcystic Lymphatic Malformations and DSAP
Palvella Therapeutics will present three posters with new data on microcystic lymphatic malformations and DSAP at Fall Clinical D…
Pemphigus Vulgaris Therapy Pipeline Expands Beyond Rituximab
A new EMJ review details how pemphigus vulgaris treatment is broadening beyond rituximab, with pipeline candidates targeting fast…